Johnston S - Search Results

1

A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.

Prat A, Tsai YH, Pascual T, Paré L, Adamo B, Vidal M, Brasó-Maristany F, Galván P, Brase JC, Rodrik-Outmezguine V, Johnston S, Ciruelos E, Parker JS. Prat A, et al. Among authors: johnston s. Clin Cancer Res. 2020 Dec 1;26(23):6141-6148. doi: 10.1158/1078-0432.CCR-20-2793. Epub 2020 Sep 22. Clin Cancer Res. 2020. PMID: 32962980 Clinical Trial.

2

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M. Johnston SR, et al. Cancer Res. 1995 Aug 1;55(15):3331-8. Cancer Res. 1995. PMID: 7614468

3

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M. Johnston SR, et al. Cancer Res. 1994 Nov 15;54(22):5875-81. Cancer Res. 1994. PMID: 7954417 Clinical Trial.

4

Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.

Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC. Johnston SR, et al. Cancer Res. 1997 Sep 1;57(17):3723-7. Cancer Res. 1997. PMID: 9288779

5

Oestrogen receptor mutants and variants in breast cancer.

Dowsett M, Daffada A, Chan CM, Johnston SR. Dowsett M, et al. Among authors: johnston sr. Eur J Cancer. 1997 Jul;33(8):1177-83. doi: 10.1016/s0959-8049(97)00100-7. Eur J Cancer. 1997. PMID: 9301439 Review.

6

Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

Newby JC, Johnston SR, Smith IE, Dowsett M. Newby JC, et al. Among authors: johnston sr. Clin Cancer Res. 1997 Sep;3(9):1643-51. Clin Cancer Res. 1997. PMID: 9815855

7

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. Dowsett M, et al. Among authors: johnston sr. Clin Cancer Res. 1995 Dec;1(12):1511-5. Clin Cancer Res. 1995. PMID: 9815951 Clinical Trial.

8

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC. Johnston SR, et al. Clin Cancer Res. 1999 Feb;5(2):251-6. Clin Cancer Res. 1999. PMID: 10037172

9

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE. Dowsett M, et al. Among authors: johnston sr. Clin Cancer Res. 1999 Sep;5(9):2338-43. Clin Cancer Res. 1999. PMID: 10499602 Clinical Trial.

10

Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.

Smith IE, Johnston SR, O'Brien ME, Hickish TF, de Boer RH, Norton A, Cirkel DT, Barton CM. Smith IE, et al. Among authors: johnston sr. J Clin Oncol. 2000 Jun;18(12):2378-84. doi: 10.1200/JCO.2000.18.12.2378. J Clin Oncol. 2000. PMID: 10856097 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,407 results

Search Page

Filters